GlobeNewswire Inc.··Urogen Pharma Ltd.Bladder Cancer Survey Reveals High Recurrence Fear, Procedural Burden Among Patients
BCAN survey of 1,100+ bladder cancer patients shows 80% experience recurrence fear, exceeding 90% in under-50 cohort. UroGen emphasizes need for treatments balancing tumor control with quality of life.
URGNquality of lifebladder cancer